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ABSTRACT 
Angiogenesis is the process by which new blood vessels form from an existing 
vasculature. The degree of angiogenesis and the character of the resulting microvascular 
beds vary between different healing environments such as wound healing and tumor 
angiogenesis. These differences are due, in part, to qualitative and quantitative 
differences in the molecular function within the tissue undergoing angiogenesis. For this 
study, these two types of angiogenic environments were created in mice and 
characterized on a gene expression level by utilizing cDNA microarrays. A DNA 
microarray containing 58 mouse genes from many different molecular classes relevant to 
angiogenesis was manufactured and tested. Optimal conditions and protocols for the use 
of microarray technology were designed and implemented. Results show that a polymer-
induced angiogenic wound healing response differs greatly in its transcription profile 
from a tumor, suggesting that different types of angiogenesis occur in different 
environments. 
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INTRODUCTION 
cDNA MICROARRAYS 
With the advent of DNA sequencing and the recent surge in large scale DNA 
sequencing projects and comprehensive cDNA library surveys, the amount of sufficient 
data available regarding complete genomes has increased exponentially (13). Currently, 
the complete genomes of nearly a dozen microbes have been sequenced and in the next 
few years those of several more metazoans, including the entire human genome, are 
expected to be finished (10). With all or most of the sequence for many individual genes 
now available in data mines such as GenBank, gene expression studies from a global 
genome perspective are now possible. This transition from studying the interaction and 
function of one gene at a time to the interaction of thousands of genes simultaneously has 
spawned the new field of functional genomics (13). 
Functional genomics attempts to assign function to genes based on when and 
where the mRNA corresponding to that gene is expressed in a given biological process. 
Function is also assigned based on gene homology and sequence domains. The 
developmental, histological, and physiological patterns in which a gene is expressed 
provide clues to its biological role since only a subset of all encoded genes are expressed 
in any given cell at given time (39) (27). With the advances in technology developed for 
the experimental use of the DNA sequence information generated, mRNA expression 
differences between different cell lines and tissue are now possible ( 48). One such 
technology used for this study is cDNA microarrays ( 49). 
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cDNA microarrays allow for the simultaneous expression monitoring of 1000' s of 
mRNA's corresponding to genes in a particular cell state or condition (25) (50). This 
"chip-based" technology involves the immobilization of minute amounts of DNA 
sequences (often PCR products) on solid substrates, such as standard glass microscope 
slides. By using a printing robot (or arrayer), up to 50,000 different spots, each 
containing multiple copies of a particular DNA sequence, corresponding to a specific 
gene, can be printed onto a single microscope slide (12). The DNA sequences can be 
standard PCR products amplified by specific primer sets from known mRNA sequences 
or cDNA amplified from expression vectors containing a normalized cDNA library (thus 
containing known and unknown genes). The DNA sequences are attached to the slide 
using a variety of surface coatings, such as reactive aldehyde groups, poly-L-lysines, or 
epoxides. These surface coatings fasten the DNA sequences firmly to the surface of the 
slide through covalent or ionic bonding of the base pairs via a Schiff base reaction or an 
amide bond. 
The basic premise behind DNA microarrays involves the fact that each DNA 
strand carries with it the capacity to recognize a uniquely complementary sequence 
through base pairing (Figure 1 ). This process of recognition, or hybridization, is 
extremely specific and highly parallel, thus allowing for the query of all spotted DNA 
sequences at the same time (7). Additionally, the sequence recognized can be of RNA, 
DNA, or cDNA origin. Therefore, DNA microarrays are basically an extension of classic 
Southern, Northern, and dot blots used to identify and quantify nucleic acid species in 
biological samples (43) (12). The amount of RNA (or DNA or cDNA) corresponding to 
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Figure 1. 
Arrayed sections of genes on the glass slide hybridize with labeled cDNA probe from the 
two samples compared via complementary base pairing between homologous sections. 
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a gene that hybridizes to its complementary DNA sequence spotted on the microarray is 
indicative of its concentration (and thus expression level) in the particular RNA pool of 
interest. 
Since the amount of DNA printed per spot on the microarray can vary, RNA 
species from two different samples are used in the hybridization. This is possible since 
differences in gene expression between samples (such as when and where the gene is 
expressed or how it changes across different biological situations) is often what matters 
most in determining the function of the gene and not the absolute abundance the mRNA 
transcribed from that gene. By using two different RNA pools, a differential expression 
pattern is acquired for the genes of interest relative to a control or normal state (12) 
(Figure 2). The result is a transcription profile of the genes that are upregulated or 
downregulated in one condition vs. another. 
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In performing these experiments, two different RNA pools are directly compared 
by labeling each of them with a spectrally distinct fluorescent dye. The mRNA from each 
total RNA sample is labeled with a different fluorescent dye in a 1st strand cDNA 
synthesis reaction (33). The dyes typically used are Cy3-dUTP and Cy5-dUTP because 
they have good incorporation rates relative to other fluorochromes and are widely 
separated in their excitation and emission fields by a configured laser scanner (11). The 
two samples are pooled together and hybridized to the microarray simultaneously. The 
relative abundance of a gene present in the two samples is assayed by measuring the ratio 
of the fluorescence intensities of the two dyes present within the cDNA that hybridized to 
its complementary DNA sequence (or spot) on the microarray (12). This ratio is then 
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Figure 2. 
Scheme for comparing the differential expression level of genes from two different RNA 
samples using cDNA microarrays. 
Tissue or Cells 
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! 
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~ / 
,--------. 
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• • • 
• • • 
• • • 
g1·ccn = mRNAs unique to condition 1 
red = mRNAs unique to condition 2 
U, . n It 
black = mRNAs absent from both conditions 
correlated to a fold increase or decrease of a gene between the two samples hybridized. 
Collectively, genes are then grouped into specific fold change categories and graphed 
using analysis algorithms such as self organizing maps (SOM's) or cluster analysis in 
order to elucidate functionality (8) ( 49). 
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As mentioned previously, making and using DNA microarrays requires two 
pieces of hardware. The printing robot (or arrayer) spots the DNA in nanoliter volumes 
using single or multiple printing tips (9). These printing tips pick up the DNA 
(suspended in 2X SSC) in a variety of ways, usually via capillary action, from 96 or 384 
well microtiter plates and spot the DNA onto the surface of the slides. As many as 100 
slides can be made concurrently using this method with the arrayer washing each printing 
tip before moving on to the next gene (11). The second piece of hardware needed is a 
microarray scanner, which images the hybridized microarrays (12). The scanner is 
configured to shine two different wavelengths (or more) of light corresponding to the 
excitation levels of the fluorochromes incorporated into the cDNA that have hybridized 
to the slide surface. Currently, many different scanners are commercially available, each 
having different capabilities and limitations. 
Once the hybridized microarray has been imaged, analysis software is needed for 
gene quantification. The purpose of this software is to reduce an image of multiple spots 
of varying intensities into a table containing a measure of the ratio of intensities. 
Although seemingly straightforward, this is more difficult than anticipated ( 4). 
Inhomogeneities in the slide surface and background noise brought about by unpurified, 
labeled cDNA pose problems for reliable results. Additionally, printing integrity and 
spot quality from slide to slide is an issue that has yet to be resolved. Many different 
microarray analysis software packages are currently available through the industry or 
have been developed privately by individual research labs (4). 
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In order to fully utilize the tremendous amounts of data that come out of every 
hybridization, the development of some type of "gene expression data mine" for 
collecting, storing, querying, and analyzing data is needed as well. Currently, only a 
handful of research labs have such capabilities and the ability for outside labs to access 
them are not possible. In order to create this data mine, a data warehouse must first be 
designed that can integrate studies from all over the world, much like GenBank does for 
DNA sequences today. The database will steadily build as more and more gene 
expression studies are performed ( 4). Construction of such a resource-based warehouse 
is a difficult process to undertake. 
Finally, due to the fact that DNA microarray technology is so new, no set 
protocols exist for any one step. As noted earlier, many different DNA attachment 
chemistries are available through the industry as well as printing tips, laser scanners, 
hybridization chambers, and printers. Additionally, hybridization buffers and conditions, 
labeling ofmRNA with fluorochromes, purification oflabeled cDNA, and microarray 
processing conditions were all components that needed to be resolved as well. For any 
research lab, these parameters must be optimized. 
Overall, as described previously, DNA microarrays are and will continue to be a 
very powerful tool in looking at the expression levels of mRNA. Recent publications 
show that the detection limit of DNA microarrays allows for the monitoring of transcripts 
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present as low as 1:500,000 in the total RNA pool (40). Also, the sensitivity of the 
microarray system is such that increases or decreases in expression levels as low as two 
fold are detectable using the two-color fluorescence system. Further studies have shown 
that absolute mRNA levels detected by DNA microarrays are similar when correlated to 
Northern Blots, depending on the nature of the experiment (3). Additionally, the 
expression levels ofmRNA with DNA microarrays have been shown to be in agreement 
with results from in situ hybridization studies (29). This being the case, along with the 
fact that thousands of genes can be measured differentially at the same time for any 
biological system, provides solid insight as to why DNA microarrays are so powerful and 
very useful to labs using molecular or cellular biology for gene expression studies. 
The adaptable nature of the fabrication and hybridization methods allows for 
DNA microarrays to be widely used. By using a BLAST search, base pair sequences for 
genes of interest or genes similar in sequence to known genes (EST's or expressed 
sequence tags) can be identified (28). Therefore, the only limitation is the number of 
sequences available in the database and the strength of the microarray experiments 
designed relies on the number and particular elements chosen. Thus, biologically 
complex processes involving the interplay of many genes can be chosen as worthwhile 
experiments for microarray studies. 
ANGIOGENESIS 
Angiogenesis is a process by which new vasculature sprouts from quiescent, 
existing vasculature. It occurs in utero during embryonic and fetal development and in 
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certain physiological and pathological situations which are accompanied by the abnormal 
high or deficient growth of new vessels during post-natal life (34) (52). Examples of 
physiological situations where angiogenesis occurs include the follicle and corpus 
luteum, in the uterus during ovarian and menstrual cycles, and during pregnancy (34). 
Pathological situations in which it can occur include wound healing, inflammation, 
ischemia, and tumor formation and growth (32). Under conditions of reproduction, 
development, and wound repair, angiogenesis is turned on (regulated) for brief periods of 
time and then completely inhibited (20). Under other conditions, such as tumor growth, 
angiogenesis is constantly underway. 
The term angiogenesis was first coined in 1935 to describe the formation of new 
blood vessels in the placenta (19). Since then, many different assays have been 
conducted to try and identify the angiogenic factors responsible for the sprouting of 
capillaries. In these in vivo assays, material to be tested is placed in an area that has a 
low background of pre-existing vessels yet will allow the formation of new capillaries. 
Among the many areas chosen for study of angiogenesis in the past were the hamster 
cheek pouch (22), the rabbit ear chamber, the chick choriolallantoic membrane (16) and 
the rabbit cornea (21 ). 
Currently, angiogenesis is thought to occur in an ordered sequence of events (14). 
Briefly, the basement membrane surrounding the endothelial cell tube is locally degraded 
by the release of collagenases and proteolytic enzymes (plasminogen activators) from the 
microvascular endothelial cells (34). The endothelial cells underlying the degraded cell 
tube then change shape and invade/migrate to the surrounding stroma by chemotactic 
20 
mechanisms. This invasion/migration is coupled by proliferation of the endothelial cells 
at the leading edge of what becomes the migrating column. Just behind the advancing 
front, a region of differentiating endothelial cells that are no longer proliferating change 
shape and tightly adhere to each other to form the lumen. Finally, the sprouting tubes 
fuse and coalesce into loops, allowing for blood to begin circulation in the newly formed 
vessels (24) (32) (52). 
The complexity of angiogenesis suggests the existence of multiple controls 
involving many different angiogenic factors. Studies performed on gene knockout mice 
have shown that vascular endothelial growth factor (VEGF) and its tyrosine kinase 
receptors Flk-1 and Flt-I (42} and the activating angiopoetin ligands (23) and their 
receptors TIE-I and TIE-2 (38) all produce lethal embryonic phenotypes resulting in 
defects from angiogenesis (51) (2). Also known to be involved with blood vessel 
formation are the transforming growth factors (TGF-f3 l and TGF-f32) (19), the ephrin 
ligands B2 and B4 and receptor eph B2 (45), and tumor necrosis factor (TNF-cx.). Many _ 
other classes of molecules may also be involved, including matrix molecules, cell-cell 
adhesion molecules, cell-matrix adhesion molecules, matrix enzymes, inflammatory 
genes, endothelial and smooth muscle cell specific differentiation genes, transcription 
factors, hypoxia induced and apoptosis induced genes (35). 
Recent work has emphasized that a genetic switch program exists to regulate 
angiogenesis. This "angiogenic switch" is thought to involve a shift in the balance of 
angiogenesis factors and inhibitors. Angiogenesis is quiescent when inhibitors are 
present in proper amounts and angiogenesis is active when factors are high and/or 
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inhibitors are low (24). However, the detailed genetic changes and their effects on 
angiogenesis in physiological situations such as development and pregnancy and in 
pathological situations such as healing responses and ischemia are poorly understood (6). 
Because of this, the intent of this study was to use DNA microarrays to observe the 
expression levels of most of the genes believed to be involved in a controlled angiogenic 
response in order to elucidate the genetic program used by endothelial cells to achieve 
this response. 
In order to produce an angiogenic environment with which to study, a controlled 
healing response was created in mice. Sehl et. al recently described a process by which 
controlled reponses to injury can be obtained from rat hearts that produced viable tissue 
and mRNA samples (41). Furthermore, it has been shown by Williams et al. that healing 
associated with expanded polytetrafluoroethylene ( ePTFE) implants in rats is specific to 
the nature of the porosity or surface modification of the polymer implant (5). 
Specifically, small pores 30 µm in size contribute to the formation of a fibrous capsule 
while larger pores of 60 µm in size allow for endothelialization in the subcutaneous 
region of the rat haunch after five weeks of implantation (36) (37). Also, denucleation 
(removal of air trapped within the interstices of porous ePTFE) and surface modification 
of the polymer, such as the deposition of extracellular matrix onto the polymer surface, 
show the absence of a fibrous capsule and the formation of new blood vessels within and 
around the ePTFE in rats after 5 weeks (5). More recent results have shown that ePTFE 
has similar effects in mice. This difference in angiogenic responses based on the 
implantation of specific forms of ePTFE provides a good model with which to identify 
angiogenesis-specific gene expression. 
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The series of experiments designed for this study utilized the fact that the amount 
of angiogenesis associated with a wound-healing response can be controlled by the 
implantation of modified and unmodified ePTFE in the subcutaneous position of the rear 
haunch in mice. Surface modified ePTFE was manufactured by allowing 11-4 cells (a 
cancerous cell line that exhibits a pro-angiogenic activity) to deposit extra-cellular matrix 
onto the surface of the polymer in a process called sodding as described by Ahlswede (1). 
This modified form of ePTFE, when implanted, induces angiogenesis within and around 
the polymer. Unmodified ePTFE induces low amounts of angiogenesis when implanted 
and thus serves as a baseline control. By explanting the polymers and the surrounding 
tissue from the mice, and by hybridizing the labeled mRNA isolated from each sample to 
a microarray containing many angiogenesis-specific genes, a transcription profile of the 
genes involved in angiogenesis was obtained. The time point of five weeks was chosen 
in order to capture the angiogenic profile at the stage when fully developed vasculature is 
present. The set of genes included on the microarray consisted of many classes of 
molecules as discussed by Risau et al. (35), Folkman et.al. (17) (18), Carmeliet et.al (6), 
and Hanahan et.al {24) and is shown in Table I. The set represents all of the genes for 
mice that have sequence available in GenBank and are considered relevant to 
. . 
ang1ogenes1s. 
An additional angiogenic environment used for this study was solid tumors 
present in the muscle tissue (sarcomas) on the bodies of mice. Tumors provide a good 
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source of angiogenesis since the main requirement for a tumor to survive and grow 
beyond a certain size involves a continuous supply of fresh blood and hence the 
formation of new vasculature (47). Gene expression in such a system is highly 
uncharacteristic and provides an interesting situation with which to look at gene function 
and interplay. Additionally, studies have shown that angiogenesis occurs in a growing 
tumor constantly until the host dies or the tumor is eradicated (15). Thus, inhibition of 
angiogenesis in a tumor is thought to be a viable approach to therapy for patients 
suffering from solid tumor growth (26). 
Tumor angiogenesis is thought to be induced by a permanent shift in the balance 
between angiogenic factors and inhibitors. Recent studies suggest that cancer cells, 
vascular endothelial cells, and other stromal cell types all release angiogenic factors that 
offset the amount of inhibitors, causing the formation of new vessels (31 ). However, is it 
unclear which genes become activated or down-regulated in tumor angiogenesis because 
the molecular characteristics of such a system are again ill-defined ( 46). By explanting 
the tumor and hybridizing its labeled mRNA to DNA microarrays containing most of 
these angiogenic factors and inhibitors as mentioned before, identification of the core 
group of genes critical to the formation of the new vasculature may be elicited. 
Additionally, by comparing the transcription profiles obtained for each of the 
angiogenesis environments studied, differences in groups of genes upregulated or 
downregulated should be present, corresponding to the different types of angiogenic 
responses observed. 
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MATERIALS AND METHODS 
Arrayed Gene Sequences and Control Sequences. 
Each of the 58 genes spotted onto the array was mined from the GenBank 
database (http://www.ncbi.nlm.nih.govQ. The genes were chosen because of their 
relevance to angiogenesis as implied by the literature. The sequences themselves are all 
mRNA sequences and constitute either a partial or complete coding sequence of the 
arrayed gene. They range in length from 600 base pairs to 7000 base pairs. The entire 
panel of genes is listed in Table I. 
The two control genes used were chlorophyll alb binding protein (GenBank 
accession number 187D7T7} and plant thioredoxin (GenBank accession number 
185N8T7) cDNA from Arabidopsis thaliana cloned into Lambda zip-lox vector and 
propagated in E.Coli. Both of these EST sequences are flanked by T7 RNA transcription 
start sites. The two clones were a gift from Dr. Betsy Pierson from the Department of 
Plant Sciences at the University of Arizona. 
Primers. 
Primers for each of the angiogenesis related genes were designed using the Primer 
3 program (http://waldo.wi.mit.edu/cgi-bin/l}rimer/primer3.cgi}. Each primer was 20 
base pairs long and contained a single CG clamp at the 3' end. Each primer set was 
designed to amplify a region of300-600 base pairs in length from the more variable 3' 
region of the mRNA sequence mined for each gene. The primers were obtained from 
Angiogenesis-Specific Genes 
Angiopoetin-2 
Tie-I 
Tie-2 
VEGF-A 
Flt-I 
Flk-I 
Ephrin-B2 
MDK-5 
Collapsin-I 
Neuropilin- I 
Cell-Cell Adhesion 
Cadherin-3 
Cadherin-VE 
Cadherin-N 
PECAM 
ELAM 
ICAM 
Connexin 43 
CD34 
Transcription Factors 
EGR-I 
NFkB 
ETS-I 
Vezfl 
GATA-4 
Jun 
Fos 
MEF-2 
Inflammation 
INOS 
IL-lex. 
Table I 
Gene List 
Growth Factors 
FGF-1 
FGF-2 
FGFR-2 
TGFB-1 
TGFB-2 
TGFBR-2 
Endoglin 
sMAD-7 
Cell-Matrix Adhesion 
Integri n-cx. v 
Integrin-cx.6 
Integrin-BS 
Integrin-B 1 
Matrix Molecules 
Laminin-5 
Collagen-I 
Collagen-IV 
Thrombospondin-I 
Thrombospondix-11 
Vitronectin 
Fibronectin 
Matrix Enzymes 
MMP-9 
TIMP-2 
MMP-MT 
Stromelysin-I 
Endothelial Cell Differentiation 
SERCA3 
vWf 
eNOS 
NK-1 receptor 
Smooth Muscle Cell Differentiation 
cx.-actin 
smooth muscle myosin 
SM22cx. 
Control Genes 
Thioredoxin (plant) 
Chlorophyll A/B Binding Protein (plant) 
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Integrated DNA Technologies (http://www.idtdna.com). A complete listing of the 
primers designed for each gene as well the sequences for the Cy-3 and Cy-5 dCTP 
positional marker oligos (Integrated DNA Technologies) is listed in Appendix A. 
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Primers used for the control genes were standard M13 forward and M13 reverse 
sequencing primers (Integrated DNA Technologies) which recognize sequence flanking 
each clone. Their sequences are listed below. 
Ml3 Forward: 5'-CCCAGTCACGACGTTGTAAAACG-3' 
M13 Reverse: 5'-AGCGGATAACAATTTCACACAGG-3' 
PCR Reactions and Components for the 58 genes. 
100 µl PCR reactions were performed on each of the 58 genes using PCR 
programs designed in the lab. The source the PCR template was RNA extracted from a 
day 7 mouse embryo weighing approximately 300 mg or an adult mouse uterus. The 
RNA was extracted using the RNAZol B isolation kit (Tel-Test, Inc. Friendswood, 
Texas) and was converted to 1st strand cDNA using the RT-PCR protocol (Appendix B, 
protocol 1 ). A 20 µl pilot PCR reaction was performed to validate the reaction prior to 
product scale up. Subsequently, 100 µl PCR reactions were performed on each gene 
(Appendix B, protocol 2). The PCR reactions were run on one of four thermocycler 
programs named MAGIC-35, MAGIC-42, P-ACTIN, and P-ACTIN-42. 
The MAGIC-35 program is as follows: 
Step 1: 95° C for 0:01:30 
Step 2: 57° C for 0:00:50 
Step 3: 72° C for 0:01 :30 
Step 4: 95° C for 0:00:50 
Step 5 Goto Step 2 34 more times 
Step 6 59° C for 0:00:50 
Step 7 72° C for 0:05:00 
Step 8 28° C for 0: 10:00 
Step 9End 
MAGIC-42 goes to Step 2 41 more times. 
f3-ACTIN-35 has 59° C for Step 2 
f3-ACTIN-42 goes to Step 2 41 more times at 59° C in the f3-ACTIN program. 
Table II shows the list of genes and their corresponding thermocycler programs. 
PCR reactions for the control clones. 
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The 2 control clones were grown up overnight in 5 ml LB media broth containing 
5 µl ampicillin (50 mg/mL). Subsequently, the E Coli were lysed and the plasmids were 
isolated using the QIAGEN Mini prep Kit. Purified plasmids were then diluted 100 fold 
and 5 µI was used in a 100 µl PCR reaction in place of the cDNA template. The control 
products were generated with the MAGIC-35 program using the M13 forward and 
reverse primers. 
Electrophoresis of the PCR products. 
All 58 genes and the two control genes were run on horizonatal slab 1.2% agarose 
gels in TAE buffer (40.0 mM Tris-HCl and 5.0 mM NaOAC) to check for proper size. 2 
µI of ethidium bromide (10 mg/mL) was added to each gel for staining purposes. 5 µl of 
MAGIC-35 
TIE-I 
TIE-2 
Integrin-A6 
Endoglin 
Integrin-B I 
Integrin-A V 
ANG-2 
SMCa-Actin 
Vwf 
INOS 
FLT-I 
Vezfl 
TGFBI 
TGFB2 
sMAD-7 
SM22a 
TGFBR2 
Cadherin-N 
Cadherin-VE 
Integrin BS 
Connexin43 
NK-I Receptor 
SERCA3 
ETS-I 
FGF-I 
FGF-2 
FLK-I 
Cadherin-3 
EGR-I 
ELAM-I 
FGFR-2 
ICAM 
NFkB 
Table II 
Master PCR Program List 
MAGIC-35 
Collagen-4 
Thrombospondin-1 
Thrombospondin-2 
TIMP-2 
Fibronectin 
Fos 
eNOS 
Jun 
IL-la{uterus cDNA) 
GATA-4 
MEF-2 
Neuropilin 
MTMMP 
MMP-9 
Ephrin-B2 
Vitronectin 
Cl:Il..ORO 
THIO 
B-Actin 
VEGF-A 
Collagen-I 
CD34 
Collapsin 
SMC-myosin 
MDK5(uterus cDNA) 
PECAM 
B-Actin-42 
Stromelysin-1 
MAGIC-42 
Laminin-5 
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each PCR reaction was added to each well and the gels were visualized under longwave 
UV light. 
PCR Product and Control Purification. 
PCR products were purified by adding ½ volume 8 M ammonium acetate and 2 ½ 
times volume 100% pure ethanol. The products were stored at -80° C for 1 hour and 
pelleted at 4° C (max. speed, 15 min.) using a Beckman tabletop centrifuge and washed 
with 200 µl 70% ethanol (max. speed, 5 min). The products were resuspended in 2X 
SSC {17.5 g 3M NaCl, 8.8 g 0.3 M Na32H20, 100 ml H20) at a final concentration of 3 
µg/10 µI. 
Sequencing of Generated PCR Products. 
PCR products from ten genes were sequenced using the DNA sequencing center 
at the University of Arizona. 5 µI samples were submitted at 200 ng/ml and results 
obtained were verified against the GenBank sequences. 
Coating of Slides. 
5 slide chemistries were identified for this study: 2 silylated epoxides, 1 
commercial coating (CEL) and 2 proprietary epoxides from S2. Epoxide slide I was 
made with 3-(2,3-Epoxypropoxy)propyltrimethoxysilane (Gelest, CO) and is shown in 
Fig Ja. Epoxide slide II was made with 2-(3,4-Epoxycyclohexyl)ethyltrimethoxysilane 
(Gelest, CO) and its structure is shown in Fig. Jb. Slides from CEL and S2 were 
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Figure 3. 
Non-commercial slide chemistries (epoxides) coated in the lab for comparison against 
commercial products. 
a) 
a) Chemistry for epoxide coating I: 
3-(2,3-Epoxypropoxy )propyltrim ethoxysilane 
b) Chemistry for epoxide coating II: 
2-(3,4-Epoxycyclohexyl)trimethoxysilane 
b) 
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supplied precoated. The two epoxide coatings were applied in the lab. Solutions 
containing each of the above epoxides were made by diluting 7-ml of the respective 
epoxide in 350 ml of a 99% hexane solution (Aldrich) for a 2% final cocnetration in a 
glass-staining jar. Three separate glass staining jars containing 3 50 ml of a 99% hexane 
solution were set-up next to the 2% epoxide/hexane solution. 100 pre-cleaned glass 
premium microscope slides (Fisher) were wiped clean with a static free rag and placed 
into 30 well metal slide racks. Slides were coated in a fume hood by first prewashing in 
99% hexane solution for 2 minutes and followed by transfer to the 2% epoxide/hexane 
solution for 5 minutes. Slides were immediately transferred to a clean 99% hexane 
wash, submerged for 2 minutes, and washed again in another clean 99% hexane bath for 
2 minutes. The slide rack was removed and allowed to dry overnight in the hood. Slides 
were covered with tin foil while drying to avoid settling dust. Care was taken to make 
transfers between baths quickly to prevent evaporation and thus keep down background 
fluorescence. At first, 30 slides of a coating were prepared for pilot tests. For the final 
printings, 120 slides were coated at once to improve homogeneity in coatings. Cost of 
producing each of these slides was about $0.80 per slide. 
Printing of Arrayed Genes. 
Two sets of microarray printings were performed using a robotic printer 
(GeneMachines) available at the Plant Sciences Department at the University of Arizona. 
The first print involved spotting 10 genes in duplicates and also included 2 amino-
modified genes Integrin-f31 and TIE-2, which contained 5' amino-modified endgroups 
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(Integrated DNA Technologies). Additionally, a dilution series from 1/10 to 1/100000 
the normal concentration (3 µg/10 µl) of the gene Integrin-f31 and amino-modified 
Integrin-f3 l were printed to test attachment strengths. Finally, a control gene (Flt-I from 
rat) and a short oligomer containing the fluorescent nucleotide Cy-3 dCTP (Amersham) 
at 10 µMin 2X SSC were printed for a cross-hybridization and positional marker 
respectively. The genes were arrayed onto 5 different slides coated with Sigma I, Sigma 
Il, CEL, Epoxide I and Epoxide II. The genes were printed with one Telechem 
ChipMaker 2 Micro Spotting Pin (Arraylt) in the presence of ambient humidity from a 96 
well microtiter plate from IO µI samples. Each spot on the array contained ~ I nl of liquid 
and the total print time was 4 hours. Spacing between each spot was 750 µm and spot 
size was 100 µm. The layout of the prototype microarray is shown in Fig. 4. Slides 
were stored in plastic slide cases at room temperature in the dark until use. These slides 
were used to test slide coatings and demonstrate proof of principle ( see results page 52-
53). 
The second print (or "Big-Array") involved arraying 58 angiogenesis genes plus 
the 2 plant controls. Each gene was spotted in triplicate in I nl spots in a predetermined 
grid using one ChipMaker 2 Microspotting Pin. A total of two complete microarrays 
(Fig. 5) were printed on 88 slides of the chosen chemistry (Epoxide I), ten poly-I-lysine 
slides and 2 CEL slides. The printing was performed at 25% humidity and the genes 
were organized into a 96 well microtiter plate in 10 µI samples at a concentration of 3 
µg/10 µI. The total print time was 2 hours. Cy-3 and Cy-5 labeled oligomers (10 µM in 
2X SSC) were spotted at the corners of each array for visualization 
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Figure 4. 
Prototype microarray layout for the five slide chemistries printed on. 
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Figure 5. 
Layout of Big-Array. 
Each set of three dots represents I gene printed in triplicates . 
... ... ···D··· .............. . 
······D····················· 
0 = Plant Control Genes 
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purposes. The spacing between each spot was 250 µm and spot size was I 00 µm. Slides 
were stored in the desicator at room temperature until use. 
Processing of Microarrays. 
Microarray slides were rehydrated (DNA side down) in horizontal 50 ml Falcon 
tubes containing I ml ddH20 for 5 minutes at room temperature. The slides were then 
snap dried {DNA side up) on a 75° C hotplate for 3 seconds. Arrayed elements were 
circumscribed with a diamond scriber and the entire slide was blocked in 30 ml of a fresh 
sodium borohydride solution (I g NaBHi, 100 ml 100% ethanol, 300 ml PBS) for 15 
minutes at room temperature in a staining jar on an orbital shaker. The slides were then 
submerged in 95° C ddH20 for 2.5 minutes, plunged into cold 100% ethanol for 15 
seconds and dried by centrifugation (700 rpm) in vertical 50 ml Falcon tubes for 5 
minutes. The microarrays were stored in a desicator at room temperature until ready for 
use. 
11-4 Treatment of ePTFE. 
Confluent cultures ofll-4 cells were sodded onto expanded polytetrafluroethylene 
(ePTFE) polymer stock (IMPRA Inc.), 4 mm internal diameter, 30 µm intemodal 
distance, standard wall, and 5 cm in length. Cultures were trypsinized (trypsin/EDT A) 
and suspended into medium (Dulbecco's Modified Eagle Medium high glucose, 10% 
Fetal Bovine Serum, 2mM L-Glutamine, and 5 mM HEPES buffer). The cell volume 
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required to coat the luminal surface of the polymer with 2 x 105 cells/cm2 was calculated 
and the cells were pressure sodded onto the luminal surface of the ePTFE and grown in 
culture medium for 8 days. Cells were removed from the ePTFE with 40 mM ammonium 
hydroxide for 1 hour with solution changes every fifteen minutes. Following cell 
removal, the ePFTE was rinsed 3 times with di-cation free phosphate buffered saline 
(DCF-PBS). The 11-4 cell line was a generous gift from the lab of Dr. Ray Nagle in the 
Department of Pathology at the University of Arizona. Treatment of the polymer stock 
was performed by Kameha Kidd in the lab of Dr. Stuart Williams in the Department of 
Biomedical Engineering at the University of Arizona. 
Polymer Implants. 
Eight mice from the 129-SVJ strain were obtained from Jackson Labs and were 
used for this study. All ofthe mice were male and between the ages of6-8 weeks. Four 
baseline mice were implanted with unmodified expanded polytetrafluoroethylene 
(ePTFE) and four mice were implanted with 11-4 modified ePTFE. Each of the baseline 
mice were implanted with two 6 mm2 unmodified ePTFE discs and one 4 mm2 
unmodified ePTFE disc in the subcutaneous position of the rear haunch. Four 
experimental mice were implanted with two 4 mm2 114-modified ePTFE discs and one 6 
mm2 11-4 modified ePTFE disc in the subcutaneous region of the rear haunch. Mice were 
anesthetized with 0.15 ml of2.5% Avertin per 10 g of body weight and 3 incisions were 
made with a scalpel per mouse in the rear haunch position. One polymer disc was placed 
into each incision (3 per mouse) and the skin was fastened shut with a metal clamp. 
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These implantations were performed by the Williams lab. A chart of all mice implants is 
listed in Table III. 
Mouse Tumors. 
Mammary tumor cells from the cell line EMT6 were injected at two different 
points the subcutaneous region of the rear haunch of 6 a six week old mouse. Tumors 
were allowed to grow until they had achieved a size of0.5-1 cm in diameter. These 
tumors were a gift from the lab of Dr. Emmanuel Akaporiaye in the Department of 
Cancer Biology. 
Tumor/Polymer Explants and Tissue Preparation. 
Polymer explants were performed at 5 weeks post-implantation according to the 
chart. At explant, mice were again anesthetized using 0.15 ml of2.5% Avertin per 10 g 
of body weight. The entire polymer and its surrounding tissue to be hybridized to the 
microarrays were explanted, placed into labeled 6 ml cell culture tubes, and immediately 
frozen in liquid nitrogen to protect the RNA from degradation. Subsequently, the tissue 
was stored at -80° C until use. 
For removal of the tumors, the mouse was anesthetized using Avertin as described 
above. Both tumors were excised in their entirety, placed into a 6 ml cell culture tube, 
and immediately frozen in liquid nitrogen and stored at -80° C until use. 
Mouse# Sample 
92 11-4 
91 11-4 
90 11-4 
89 11-4 
85 control 
84 control 
82 control 
81 control 
Table III 
Mouse Implant Chart 
Number of Date of Explant 
Implants 
2-4rnrn l-6rnrn 2/15/00 
2-4rnrn l-6rnrn 2/15/00 
2-4rnrn l-6rnrn 2/15/00 
2-4rnrn l-6rnrn 2/15/00 
2-6rnrn l-4rnrn 2/15/00 
2-6rnrn l-4rnrn 2/15/00 
2-6rnrn l-4rnrn 2/15/00 
2-6rnrn l-4rnrn 2/15/00 
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Sample for 
Histology 
1/2 6mm 
1/2 6mm 
1/2 6mm 
1/2 6mm 
1/2 6mm 
1/2 6mm 
1/2 6mm 
1/2 6mm 
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Preparation of Labeled Probe. 
PCR products were amplified in the presence of 1 mM Cy-3 dCTP and Cy-5 
dCTP fluorochromes in 20 µI PCR reactions (Appendix B, protocol 3). Each of these 
reactions was run on the thermocycler program MAGIC-35. RNA was extracted from 
the healing tissue by re-freezing the tissue in liquid nitrogen and then crushing it (along 
with the polymer) into a fine powder using a mortar and pestle. The RNA was extracted 
from this fine powder using the RNAzol B protocol (Tel-Test, Inc.). The RNA was then 
labeled in a first strand cONA synthesis reaction in presence of 1 mM Cy-3 dCTP or Cy-
5 dCTP (Appendix B, protocol 4). 
Purification of Labeled Probe. 
Labeled PCR products were purified using G-50 microspin columns (Amersham) 
to remove unbound nucleotodies. The PCR products were concentrated by adding ½ 
volume 8 M ammonium acetate and 2 ½ times volume 100% ethanol and then by storing 
the mixture at -80° C for 1 hour. The PCR products were pelleted at 4 C (max. speed, 15 
min.) using a Beckman tabletop centrifuge. Pellets were washed with 200 µI 70% 
ethanol (max. speed, 5 min.) and resuspended in 2 µI sterile TE (Tris-EOTA) buffer and 
10 µI PerfectHyb Plus Hybridization Buffer (Sigma). 
Labeled cONA was purified by adding 1 µI 1 % SOS (1 g SOS in 1 Liter H20}, 1 
µI 0.5M EOTA (18.61 g Na2EOTA 2H20, 100 ml H20, pH-8), and 3 µ13 M NaOH. The 
mixture was stored at 68° C for 15 minutes, equilibrated at room temperature for 15 
minutes, and neutralized by adding 10 µ11 M Tris-HCI (121 g Tris-base, 800 ml H20, 
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pH-7). Labeled cDNA's were then combined and purified again by spinning through two 
G-50 microspin columns to remove all remaining unbound nucleotides. The combined 
cDNA's were concentrated by adding½ volume 8 M ammonium acetate and 2 ½ times 
volume 100% pure ethanol. The products were stored at -80° C for 1 hour and pelleted at 
4 C (max. speed, 15 min.) using a Beckman tabletop centrifuge and washed with 200 µl 
70% ethanol (max. speed, 5 min). The pellets were resuspended in 1 µl sterile TE and 12 
µl PerfectHyb Plus Hybridization Buffer (Sigma). 
Hybridization of Microarrays. 
Labeled probes were prepared for hybridization by adding 1 µl ofCoT-1 DNA 
(10 mg/ml), 1 µl poly dA oligo (8 mg/ml), and 1 µl yeast tRNA (4 mg/ml) to each sample 
which were used as blockers. The entire solution was heated for 2.5 minutes at 95° C and 
placed on ice for 30 seconds. The hybridization chamber (Arraylt) was prepared by 
positioning a post-processed microarray slide in it and adding 20 µl dH20 to each well. 
Labeled probe was then applied to the microarray slide and a glass cover slip (22 x 22 
mm) was placed on top of it. The hybridization chamber was then sealed and submerged 
in a 62° C water bath for 15 hours. 
After hybridization, the microarray slides were washed in 200 mL IX SSC/0.03% 
SOS solution for 5 minutes on a horizontal shaker. The microarrays were then 
immediately transferred to 200 mL 0.2X SSC solution and washed for 5 minutes on a 
horizontal shaker. Finally, microarray slides were transferred to 200 mL 0.05X SSC and 
washed for 5 minutes. Slides were then dried by centrifugation (700 rpm) for 5 min. in 
vertical 50 ml Falcon tubes. 
Scanning of Hybridized Microarrays. 
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Microarrays were scanned using the ScanArray 3000 (GSI Lumonics) at the Plant 
Sciences Department. Initially, 50 µm quick scans were performed to locate the 
microarrays on the slide. Then, the microarrays were scanned at 10 µm spatial resolution 
for each channel (Cy-3 and Cy-5). For both scans, the setting for PMT (percent 
maximum threshold) was 85% and the laser intensity was 90%. Images were saved as 
tiff files on zip disks and later transferred to CD using a CD burner in morphology (room 
5305, Department of Biomedical Engineering). 
Analysis of Hybridized Microarrays. 
Analysis of hybridized microarrays was performed by using the ScanAlyze 
software available at http://cmgm.stanford.edu/pbrown/. The gain was set to 4 and the 
norm was set to 1 on the initial setting screen. An overlayed image (in the form of a bit 
map file) for visual purposes was then created after the redraw key was selected for each 
microarray scanned. A computer grid containing the exact number of spots present on 
the hybridized microarrays was formed that fit on top of the redrawn overlaid image by 
selecting new grid from the options. This step was performed once and the grid was 
saved as a SAG file (ScanAlyze Grid File) and reused for each subsequent microarray 
since the same microarray in the same pattern was printed on each slide. Each grid was 
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designed with 250 µm spacing between spots and rows and the spot size was set at 12 
pixels by 12 pixels (each pixel equals 10 µm which was the resolution of the scan used). 
The grid was adjusted on a spot by spot basis so as to completely enclose the microarray 
hybridization spot into each circle present within the grid. Hybridization spots were 
adjusted by first selecting a spot using the shift and mouse keys and then by using the 
warp and tilt options. Once the grid was in place over each spot, the data was saved as a 
data file and transferred to a Microsoft Excel spreadsheet. 
Ratios of gene expression for each spot were calculated by using the following 
formulas by ScanAlyze: 
Adjusted Intensity of Cy-3 = (Cy-3 spot intensity - Cy-3 median background) 
Adjusted Intensity of Cy-5 = (Cy-5 spot intensity - Cy-5 median background) 
Expression Ratio/gene = (Adjusted Intensity Cy-5/ Adjusted Intensity Cy-3) 
The expression ratio/gene was taken to be a fold increase or decrease of that gene 
between each sample. The median background was used because it is lower in value than 
the mean background. The mean background incorporates the overall background pixel 
intensity including dust and noise while the median background does not. Thus, the data 
set is skewed in favor of the mean in terms of values assigned. The background 
measurement was taken to be the area just outside each circle for each gene defined by 
the grid. Hybridization signals greater than the background plus 1 standard deviation of 
the background were considered significant. 
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Spot quality was determined using the Komolgorov-Smirnov test which comes 
with ScanAlyze. This test removed spots from consideration that were fluorescing with 
intensity due to dust particles or noise erroneously placed (i.e. I or 2 pixels fluorescing 
brightly within an area where a spot should be and giving the impression that a spot is 
present). The test removed these spots from consideration by performing a statistical 
analysis that assigned a probability factor that there was a difference in intensity between 
where a spot should be and where the spot should not be (i.e. the values for the 
background within a particular spot on the microarray). Probability factors greater than I 
x 104 were not considered while probability factors less than I x 104 were considered as 
spots for most hybridizations. A Komolgorov-Smirnov value of greater than Ix I 04 
means the probability that the distribution between pixel sets within a grid spot is the 
same is high and thus there is no hybridization (i.e. there was no difference in pixel 
intensity between the background and the possible hybridization spot). A Komolgorov-
Smirnov value less than I x I 04 means that the probability that the distribution between 
pixel sets within a grid spot is the same is low and thus there is a hybridization present 
(i.e. there was a difference in pixel intensity between the background and the 
hybridization spot). Additionally, greater than 50% of the six spots of each gene arrayed 
(two full arrays, triplicates each array) needed to pass the above tests to be considered a 
usable spot. Thus, hybridization intensity values of each gene were taken to be the 
average value across the amount of spots passing the tests. 
Normalization of the two channels (Cy-3 and Cy-5) was performed by obtaining 
an average correlation number from the pixel ratios of genes that exhibited no change in 
ratio across the two samples compared. These genes were considered housekeeping 
genes that were expressed in equal amounts between the RNA pools studied. The pixel 
by pixel ratio for these unchanged genes was written as: 
Adjusted Cy-5 Intensity Average /Adjusted Cy-3 Intensity Average 
Or 
Adjusted Cy-3 Intensity Average/Adjusted Cy-5 Intensity Average 
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depending on which way the overall signal intensities on the microarray favored. Equal 
amounts of Cy-3 and Cy-5 fluorochrome produce different intensities of fluorescence 
depending on laser intensities, scanning properties, and the molar absorbances and 
qunatum yields of Cy-3 and Cy-5 molecules themselves. Therefore, intensities of one 
channel obtained on each microarray were either divided or multiplied by the 
normalization factor, depending on the pixel by pixel ratio calculated by the program. 
The normalization factor varied between slides and thus changed value for each 
microarray hybridization. This is because some variability exists between each 
microarray hybridization due to kinetic issues and pipetting issues. 
Using graphs, a quantitative organization of genes from highest to lowest in fold 
change was designed for each implant (11-4 modified ePTFE vs. unmodified ePTFE) at 
the 5 week time point. The same type of graph was created for the tumor/normal tissue 
hybridization experiment. Genes exhibiting a ratio of >1.5 times the amount of mRNA 
transcript present (or 0.5 fold increase) were considered to be upregulated and significant. 
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Genes exhibiting a ratio of <1.5 (or less than 0.5 fold change) were not considered to be 
changed since the sensitivity of microarrays has been shown to be about I fold. 
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RESULTS 
Microarray Elements are of Proper Size and Good Quality. 
Each of the ten PCR products arrayed onto the prototype microarrays were run 
out on 1.2% agarose gels to verify the PCR amplification protocols developed. All 
products amplified on their respective programs did not contain any non-specific 
products and had the proper base pair length. An example of a gel containing three 
prototype microarray genes Integrin-B I, Integrin-av, and Angiopoetin-2 is shown in Fig. 
6. In addition to agarose gel electrophoresis, each of the PCR products for the ten 
prototype microarray genes was sequenced by first pass at the DNA sequencing center 
located on the campus of the University of Arizona. Each sequenced PCR product had 
the correct base pair length and was of good quality (i.e. a sequence containing the proper 
number of base pairs and few ambiguities). Optimal nucleotide alignment comparisons 
of the sequenced PCR product to sequences in GenBank were also performed. Every 
analyzed element matched the appropriate gene to within 95% homology. The remaining 
5% variation was due to ambiguities in the measured sequence. An example of the 
optimal nucleotide alignment comparison for the Angiopoetin-2 element is shown in Fig. 
7. 
For the remaining 48 elements and two plant control elements printed on the Big-
Array, each was amplified by PCR in a I 00 µl reaction and quality checked by gel 
electrophoresis. Each of the 48 PCR products corresponding to one gene was run out on 
a 1.2% agarose gel. An example of a group of genes run on the MAGIC-35 PCR 
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Figure 6. 
1.2% agarose gel of three prototype microarray genes: Integrin-Bl (lane 4), Integrin-av 
(lane 5), and Angiopoetin-2 (lane 6). 
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Figure 7. 
Nucleotide optimal alignment of the PCR product angiopoetin-2 vs. the actual sequence 
of mouse angiopoetin-2 showing a 95.49% match of the base pairs. 
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program is shown in Fig. 8a. For elements giving a weak product, such as Interleukin-la. 
(Fig. 8a, lane 11 ), an additional 100 µl PCR reaction was performed to increase the total 
amount of the product for printing. Fifty of the 58 PCR reactions (86%) run exhibited a 
single band of expected size. The elements for PECAM (lane 8), VEGF-A (lane 9), and 
CD34 (lane 10) shown in Fig.Sb all had additional products that were not removed. 
Additional elements exhibiting multiple bands were TGFBR-2, ELAM-I, MDK-5, and 
Stromelysin. Thus, these genes were arrayed with the potential to detect more than one 
expressed gene. However, it seems likely that these multiple bands might represent 
isoforms of the same gene, since each of these genes come from families known to have 
multiple isoforms. 
Epoxide I is Comparable to the Commercial Slide Products. 
In order to assess which slide chemistry produced the best signal to noise ratio for 
the lowest cost, prototype microarrays were printed on 5 different slide chemistries 
consisting of three commercially available products (CEL, S 1, and S2) and two epoxide 
slide coatings identified by the lab. In order to compare the slides to each other, PCR 
products from Integrin-PI, Integrin-a.v, and Integrin-P4 cDNA's were synthesized in the 
presence ofCy-3 or Cy-5 dCTP according to the protocol shown in Appendix B. By 
labeling PCR products, the amount of labeled DNA to be applied to the microarray will 
be in excess to the amount of DNA arrayed on the slide surface. Integrin-P I PCR 
products were amplified with both fluorochromes. Integrin-a.v was labeled with Cy-3 
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Figure 8. 
Electrophoresis of PCR products from genes run on a) MAGIC-35 and b) ~-Actin 
thermocycler programs. 
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and Integrin-(34 was labeled with Cy-5. Equal amounts of these PCR products (~I µg) 
were hybridized to separate microarrays made from each of the 5 slide chemistries. The 
microarrays were scanned at 10 microns with a laser intensity of90% and a PMT of85%. 
SI and epoxide II were extremely noisy and exhibited no hybridization signals. As 
expected, Integrin-(31 appeared yellow since equal amounts of Cy-3 and Cy-5 PCR 
product was hybridized, Integrin-av appeared red (Cy-3 only), and Integrin-(34 appeared 
green (Cy-5 only). In addition, hybridization signals were present for the Integrin-131-
amino modified spots, as well as the 1/10 dilution spots oflntegrin-(31 and Integrin-13 I-
amino modified. No cross hybridizations to other elements were evident. An example of 
a hybridization experiment to prototype microarray 95 (CEL) is shown in Fig. 9. 
Next, particular ratios of labeled PCR products for elements selected on the 
prototype microarrays were prepared in order to test the accuracy of each microarray 
type. Integrin-av was mixed in a 16:1 ratio in favor ofCy-5, Tie-2 was mixed 8:1 in 
favor ofCy-5, Integrin-(31 was mixed 4:1 in favor ofCy-3, and Endoglin was mixed 2:1 
in favor ofCy-3. These mixtures were combined and hybridized to each of the 
microarrays prepared for the 5 different chemistries. Again, the slide coatings that gave a 
proper fold change pattern presented by the labeled PCR products were the CEL, S2, and 
epoxide I chemistries. SI and epoxide II produced too much noise and had no visible 
hybridization signals. Hybridization signals were analyzed using ScanAlyze, and the 
results compared to the expected values. In all but one case, ratios detected by the 
microarrays were very similar to the expected values. One of the elements for Integrin-
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Figure 9. 
Visual image of prototype microarray 95 showing equal amounts oflntegrin-Bl labeled 
with Cy-3 and Cy-5 (yellow), Integrin-av labeled with Cy-3 only (red), and Integrin-B4 
labeled with Cy-5 only (green). 
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-av exhibited an erroneous ratio. Visible inspection of that element after hybridization 
revealed an incomplete spot. Later studies revealed the importance of spot quality in 
producing accurate results (see discussion). A graph of prototype microarray 27 (epoxide 
I} intensities and ratios is shown in Fig. 10. 
Raw background and hybridization signal intensities from these experiments were 
compared between the three working chemistries (CEL, S2, and epoxide I). Raw 
hybridization intensities between the three different slide chemistries were similar for 
each of the hybridized elements. One exception, the amino-modified Integrin-Pl 
element, exhibited higher hybridization signal on CEL than for S2 and epoxide I. A 
graph of the raw hybridization intensities for prototype microarrays 6 (CEL), 25 (epoxide 
I}, and 42 (S2) is shown in Fig. 11. In contrast, raw background signals were remarkably 
lower for the epoxide I than for the other two coatings (Fig. 12). The value for the 
background of epoxide I was on the order of 5 times less than CEL and 10 times less than 
the S2. Due to these results, all remaining hybridizations performed for this study were 
done with the epoxide I slides. 
Quality Control Check of the PMT and Laser Settings Used for the Scanner. 
In preliminary experiments, it became evident that the scanner settings used to 
image hybridized microarrays were important for obtaining reliable data. To determine 
the proper PMT (percent maximum threshold of the detectors) and laser intensity 
settings, adjustments to both parameters were made during the scanning of the 
hybridizations on the prototype microarrays. Laser intensity was decreased incrementally 
Figure 10. 
Results of fold-change expression pattern for PCR products hybridized to prototype 
microarray 27. The lines represent intensity of the signals and the bars represent fold 
changes. 
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Figure 11. 
Raw hybridization intensities of PCR products on prototype arrays for three slide 
chemistries: array 6 (CEL); array25 (epoxide I); array 42 {S2). 
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Figure 12. 
Raw median background intensities of PCR products on prototype arrays for three slide 
chemistries: array 6 (CEL); array 25 (epoxide I); array 42 (S2). 
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from 95-75% with a constant PMT of85% and the slide scanned until hybridization 
signals dropped off in detectable value to <200 for the Integrin-J3 l spots that had been 
diluted I 00 fold and I 000 fold on the prototype microarrays. This cut-off laser intensity 
was determined to be 90% for epoxide I, whereby low hybridization signals could barely 
be detected for the 100 and 1000 fold dilution spots oflntegrin-J3 l (Table IV). PMT 
settings were determined in a similar fashion, whereby the settings were decreased 
incrementally from 90%-60% (with constant laser intensity of90%) on prototype 
microarrays, the slides scanned, and the results obtained compared to the proper fold 
change patterns seen with 90-85 (laser intensity to PMT) settings. The fold change 
patterns were compromised when the PMT was too low or too high, as was the 
hybridization signal intensity when the laser intensity was too low. Thus, the settings of 
90% laser intensity and 85% PMT were used since proper ratios were obtained without 
compromising image quality. 
Verifying printing of the 58-gene Big-Array. 
Labeled PCR products were hybridized to the Big-Arrays printed on epoxide I 
(see Materials and Methods) in equal amounts to test for cross hybridization and spot 
printing quality. An image of the hybridization experiment involving five elements 
(iNOS, Thrombospondin-1, Cadherin-VE, FLK-1, and Vez-fl) is shown in Fig. 13. 
Positive hybridization signal for each of the genes was present on triplicate spots, 
verifying that the arrayer spotted each gene correctly across three spots. No cross-
hybridization was observed to other elements. The raw intensity values for the rest of the 
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Table IV. 
Detectability oflntegrin-B 1 (1/100 dilution) and Integrin-B 1 (1/1000 dilution) on 
epoxide I. 
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Figure 13. 
Hybridization of fluorescently labeled PCR products iNOS (1 ), Thrombospondin-1 (2), 
and Cadherin-VE (3) with Cy-5 (red) and FLK-1 (4) and Vez-fl (5) with Cy-3 (green) to 
Big-Array 16. 
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genes not hybridized to the Big-Array were equal to background levels for both the Cy-3 
and Cy-5 channels. To test the precision of the Big-array, 15 µg of mouse total heart 
RNA was labeled in the presence ofCy-3 dCTP fluorochrome and 7.5 µg ofit was 
hybridized to Big-Array 12 (Fig. 14). All of the genes had raw hybridization signals 
associated with them in varying amounts. The signals ranged from ~2000 to ~ 17,000 in 
intensity. Additionally, each of the three spots within a triplicate associated with one 
gene had similar hybridization signal values. Figure 15 shows the individual 
hybridization values of the triplicates for 5 hybridized genes. Figure 16 shows the mean 
of the hybridization intensities for each of the triplicate sets along with the standard 
deviations. No hybridization occurred to the two plant genes Thioredoxin and 
Chlorophyll alb binding protein. The raw intensity values of these two genes were 
consistent with the low overall background signal inherent to the epoxide I slides. 
To test the accuracy of the Big-Array, equal amounts (7.5 µg) of total mouse heart 
RNA were labeled with Cy-3 and Cy-5 and hybridized to Big-Array 23. Upon imaging 
the scanned slide and normalizing the data, all of the elements exhibited a yellow color, 
indicating equal amounts ofmRNA from each sample (heart RNA, Cy-3; heart RNA, Cy-
5) were hybridized to each arrayed element (Fig. 17). Raw hybridization intensities 
across triplicates within the microarray were very similar for each channel and mirror the 
small deviations obtained from Big-Array 12. A scatter plot graph of the two different 
fluorochrome intensities for all the genes was generated to show the correlation between 
the sets of data (Fig. 18). Finally, no hybridization signal was detected on the two plant 
control genes. 
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Figure 14. 
Image of7.5 ug total heart RNA labeled with Cy-5 hybridized to Big-Array 12. 
Figure 15. 
Raw Cy-5 hybridization signals of 5 genes from Big-Array 12 (heart RNA) showing 
similar values across triplicates representing each gene. 
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Figure 16. 
Mean Cy-5 hybridization intensities with standard deviations for 5 genes on Big-Array 
12. 
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Figure 17. 
Equal amounts of heart RNA labeled with Cy-3 and Cy-5 dCTP and hybridized to Big-
Array 23 . 
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Figure 18. 
Scatter plot of equal amounts of mouse heart RNA labeled with different fluorochromes 
and hybridized to Big-Array 23. 
18000 
• gene ~ 16000 
-- .,2 = 0.9921 
·-s9 
~ 14000 
.5! 
... 12000 
= ~ 
e 10000 ~ 
-~ 
i 8000 
... 6000 
... 
= ~ 
.i::: 4000 
~ 
u 2000 
0 
0 2000 4000 6000 8000 10000 12000 14000 16000 18000 
Cy5 heart RNA element intensity 
66 
11-4 vs. Unmodified Healing Tissue. 
To develop transcription profiles for the angiogenesis-related genes present on the 
microarray for the two different healing responses, gene expression in healing tissue 
surrounding 11-4 modified and unmodified ePTFE polymer implants and mouse tumor 
versus normal muscle was compared. Unmodified ePTFE polymer implants exhibited 
few new blood vessels. These blood vessels were present on the luminal side of the 
implant only, and did not span the entire healing tissue and polymer (Fig. 19a). In 
contrast, Il-4 modified ePTFE polymer implants exhibited numerous, large vessels in the 
surrounding healing tissue (Fig. 19b ). This new vasculature was present mostly on the 
luminal side, but some vasculature existed on the abluminal side. 
Differentially labeled cDNA's from Il-4 and unmodified ePTFE polymer were 
then combined and hybridized to Big-Array 5 (Fig. 20). From the hybridization image, it 
can be seen that roughly half of the genes were present in equal amounts (yellow) in both 
samples while the other half were upregulated (green) in the Il-4 modified healing tissue. 
After determining the exact ratios using the ScanAlyze program, 31/58 genes were 
upregulated at least 1.5 times (Fig. 21 ). For this microarray, no hybridization occurred 
to the negative plant control genes. Additionally, raw hybridization intensities across 
triplicates within each microarray were consistent as seen on the previous microarrays. 
Finally, the hybridization was repeated and yielded similar results. 
Tumor vs. Normal Muscle. 
Mouse mammary EMT6 tumor cells injected subcutaneously in the flank of a 
Figure 19. 
Captured images of the luminal side of the a) unmodified ePTFE and b) II-4 modified 
ePTFE five week polymer implants and surrounding tissue. 
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Figure 20. 
Image oflabeled 11-4 modified ePTFE implant tissue cDNA (green) vs. labeled 
unmodified ePTFE implant tissue cDNA (red) hybridized to Big-Array 5. 
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Figure 21. 
Transcription profile of Unmodified vs. 11-4 Modified ePTFE Implant Tissue. 
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SCID mouse will grow substantially beyond 3 cm. in diameter. This growth is thought to 
require angiogenesis. Histology of these tumors harvested at 2-3 cm. in diameter 
indicated the presence numerous, small blood vessels (data not shown). To develop 
transcription profiles for the genes present on the microarray for the tumor and the non-
angiogenic normal thigh tissue, 7.5 µg of total RNA isolated from the tumor was labeled 
in the presence of Cy-5 dCTP. Similarly, 7.5 µg of total RNA isolated from the normal 
mouse thigh tissue was labeled in the presence of Cy-3 dCTP. The labeled cDNA's 
were then combined and hybridized to Big-Array 42. From the image (Fig. 22) and 
analysis (Fig. 23), 46/58 genes are upregulated in the tumor (red), 11/58 genes are not 
changed from normal tissue (yellow), and I gene is downregulated in the tumor (green). 
For this microarray as seen previously, no hybridization occurred to the negative control 
plant genes, the overall slide background was low, and the hybridization was repeated to 
verify reproducibility. 
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Figure 22. 
Image oflabeled tumor tissue cDNA (red) vs. labeled mouse thigh tissue cDNA (green) 
hybridized to Big-Array 42. 
Figure 23. 
Transcription Profile of Tumor vs. Mouse Thigh Tissue. 
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DISCUSSION 
In assessing the performance of the microarrays manufactured and used in this 
first study, many control experiments were performed. First, prototype microarrays 
consisting often genes, two amino-modified genes, and a dilution series were printed to 
gain some experience with microarray technology and identify a suitable slide chemistry. 
These test experiments showed that no cross-hybridization was occurring on these 
prototypes, as the only spots to show any hybridization intensity were the spots that 
matched the PCR products hybridized to the microarrays. These results also gave insight 
as to the correct concentration with which to array the DNA elements. This 
concentration turned out to be 3 µg/10 µl, which is the standard within the scientific 
community. The dilutions allowed for the establishment of the microarray sensitivity, 
which was determined to be about a I 000 fold. Furthermore, the type of slide surface 
chemistry that yielded the optimum results was identified. The epoxide I coating, 
prepared in the lab, gave similar cDNA hybridization intensities and lower background 
intensities when compared with commercial products (S2 and CEL, Fig. 11 and 12), 
exhibited good precision (Figs. 15 and 16), good accuracy (Figs. 10 and 18), and did not 
require amino-modification of elemental DNA. 
A possible explanation as to why the epoxide I coated slides performed better 
than the commercial slide products with respect to signal to noise ratios is due to the fact 
that the epoxide chosen created an extremely hydrophobic surface that covalently linked 
the spotted DNA immediately after printing. This hydrophobic surface allowed for 
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printed DNA to remain in a circular pattern consistent with the pin and not spread out 
over the slide after printing, causing dilution of the DNA in some areas within the spot, as 
can occur with charged slide surfaces such as poly-I-lysine. Thus, when hybridized, this 
concentrated spot of DNA was able to promote higher and more uniform intensities than 
a non-uniform spot. Additionally, by covalently linking the spotted DNA immediately 
after printing, the DNA remained firmly attached and never was able to detach. Other 
slide chemistries, such as CEL, which are aldehyde-based, require an additional Schiff-
base reaction step to covalently link the printed DNA. This extra step may alter the 
fashion in which the printed DNA is attached to the slide surface in such a way as to 
detract from the ability of the incoming probe to hybridize, although this has been poorly 
characterized by the scientific community thus far. Another explanation for why the 
epoxide slides have a low inherent background involves the fact that the silane groups on 
the slide surface are extremely reactive toward the blocking agent used to inactivate the 
remaining reactive groups on the slide surface after printing. Once blocked, the entire 
slide is only reactive to incoming probe where DNA is bound, which prevents any non-
specific interactions the probe can have with the rest of the slide surface. Since the 
epoxide was completely blocked, or at least blocked to a degree more than the 
commercial products, minimal noise is seen post hybridization. Finally, the epoxide I 
slides prepared in the lab were cost-effective. Almost all slides made were usable and 
cost roughly $1.10, whereas 30-40% of the CEL and poly-L-lysine slides (at a cost of 
$3.00 per slide when adjusted for the defective slides) commercially available and free of 
contaminants were usable. 
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A few aspects of DNA microarray technology that appear to be extremely 
important involve the printing tip choice and RNA quality. The printing tips used for this 
study were the ChipMaker 2 Microspotting pins. While these pins exhibited almost no 
carryover from spot to spot, the quality of the spots varied greatly. These spots ranged in 
size from about 50-100 microns and some were doughnut shaped. This posed problems 
when imaging and analyzing the hybridizations using ScanAlyze since the program 
requires excellent spot quality in order to extract proper data readings. For this reason 
alone, many hybridizations had to be repeated in order to present the program with usable 
hybridization spots. Currently, there are about 5 companies which manufacture 
microarray printing tips and for future experiments this issue needs to be resolved in 
order to obtain accurate data. Another issue that greatly affects hybridization results 
involves the RNA quality. RNA that has degraded or that is not pure can add to the 
overall noise of the image and cause high background signals, which will affect the 
accuracy of the results. Additionally, poor RNA quality may lead to an increase in cross-
hybridization as this degraded RNA can take the form of an entirely different transcript 
and change the transcription profiles of the genes involved. Throughout the course of the 
study, it was learned that in order to get the best RNA for a microarray hybridization, it 
was necessary to extract the RNA immediately after the tissue was explanted. 
Some complications associated with microarray technology, such as the 
incorporation rates of the two fluorochromes and the normalization of the hybridized 
image, remain unclear. It is still not known to what extent the incorporation rates of Cy-3 
and Cy-5 dCTP's vary in the reverse transcribed cDNA and to what amount they are each 
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incorporated. This could potentially impact whether or not these fluorochromes are a 
viable way to study the changes in mRNA levels across two samples. A possible way 
around this problem is to use radioactivity, which is known to incorporate at a much 
higher amount. In this particular case, only one sample would be needed and absolute 
levels mRNA could be detected. The drawback to such a system is that a single sample 
cannot be reliably analyzed on printed DNA microarrays (such as those used in these 
studies) because not every spot printed on the microarrays has the same amount of DNA. 
Another poorly characterized issue of DNA microarrays, and a consequence of variable 
dye incorporation involves the normalization of the two fluorescent channels. 
Normalization is needed because equal amounts of Cy-3 dCTP and Cy-5 dCTP fluoresce 
at different amounts depending on scanner and the incorporation rates between the two 
flourochromes are different. The most common way to normalize a microarray 
hybridization is to use control housekeeping genes that do not change in concentration 
across the two experimental samples. Then, the entire data set is corrected to produce a 
ratio of I for these genes. However, it can be difficult to identify a gene that truly does 
not change in expression across different samples, making this normalization procedure 
difficult to use. Another way to normalize the two channels is to add up the entire 
amount of fluorescence present in each channel and then normalize each element value to 
this sum total value. Normalized values are then used to determine change in expression 
between the two samples ( 41 ). This method attempts to account for unknown variations 
in procedures and does not make any assumptions as to gene expression levels. 
However, because it is assumed that most genes represented on the microarray do not 
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change in expression, this method is best suited for large microarrays. The normalization 
procedure used for this study involved computing an average intensity of each channel on 
some of the genes that exhibited no change in expression between the samples hybridized 
and correcting the data to produce a ratio of 1 for these genes. 
A final aspect of DNA microarray technology characterized for this study 
involves the amount of total RNA needed for labeling in order for the microarray to 
detect real changes. In this study, 15 µg of total RNA was labeled into cDNA for each 
fluorochrome, with 7.5 µg of each reaction (or½ of each labeled cDNA reaction) being 
hybridized to each array. This amount is far below what is commonly reported by other 
investigators, which averages about 30-50 µg. Although 7.5 µg of total RNA is low in 
amount compared to others, detectable changes were seen by the microarrays used in this 
study. For instance, when equal amounts of two samples were labeled with different 
fluorochromes and hybridized, no change in the amount transcript within each sample 
was seen (Fig. 17). However, when the tumor tissue vs. normal thigh tissue and the 11-4 
modified ePTFE implant tissue vs. unmodified ePTFE tissue transcription profiles are 
compared, definite changes are present. This indicates that the microarray is detecting 
specific changes. Although there is no way to check that the microarray results are 
completely accurate without performing specific Northern Blots or other assays on each 
of the 58 genes used in this study. Reproducibility was obtained across the microarrays 
as well by hybridizing the remaining½ of the labeled cDNA mixture to other microarray 
slides and comparing them to the original hybridizations. This ensured that the labeled 
cDNA came from the original reactions (since reverse transciptase reactions can vary 
greatly from reaction to reaction). Also, since the chemistry used to coat the epoxide 
slides in the lab for this study has never been used by anyone else, it is possible that the 
sensitivity of these slides is better than the commercial products available. 
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An overall assessment of DNA microarray technology in the current scientific 
literature confirms that the process is still new and many improvements need to be made. 
Issues such as the ones encountered for this study are common to all users of this 
technology. Additional problems, such as the cost of supplies (which can total upwards 
of$120,000 for an arrayer and scanner), along with the cost of new printing tips and the 
fluorochromes are still very high. Furthermore, the large amounts of data that are 
extracted from every microarray experiment need to be analyzed and warehoused in some 
organized fashion. All of this, coupled with the fact that a two-dimensional, glass based 
slide system such as the type used for this study, may not in fact be the right approach. 
Currently, three dimensional polymer scaffold systems are under development, which 
allow for larger amounts of hybridization and higher signal intensities. This type of 
technology would only require the use of a configured CCD camera and not an expensive 
laser scanner. Technology such as this will be available in the near future. For the 
experiments performed here, however, the current DNA microarray technology produced 
useful and insightful findings worthy of future studies. 
For this study, DNA microarrays were used to monitor the changes in gene 
expression that occur in tissue undergoing angiogenesis in order to gain insight into the 
complex molecular mechanisms that govern the process. By using a healing tissue 
response model in mice to polymer implantation as well as a controlled tumor growth 
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model, two different angiogenic situations were created whereby the gene expression 
changes between the two situations could be observed. It is clear from the results that 
two, completely different genetic programs were utilized by the underlying tissue cells to 
induce the formation of new blood vessels within each angiogenic situation. In all, 31/58 
genes (53%) were upregulated at least½ fold in the polymer implant tissue. In the tumor 
vs. normal thigh, 46/58 genes (79%} were upregulated at least 1/2 fold while 1 gene was 
downregulated at least 1 fold in the tumor tissue. When the two transcription profiles 
were compared against each other (Fig. 24), different genes were upregulated in the 11-4 
modified ePTFE vs. unmodified ePTFE healing tissue than in the tumor vs. normal thigh 
tissue. To further characterize the difference in two transcription profiles, a scatter plot 
graph was generated that shows a low correlation number of0.34 (Fig. 25). 
For these graphs, the value of l.5X (or 0.5 fold increase) was chosen as the 
threshold value for detection of significant changes in gene expression levels. This value 
was chosen because it is conservative with respect to the actual detection limits obtained 
from microarrays. For the microarrays used in this study, the detection limit was 
probably lower. In analyzing the data associated with the mouse total heart RNA labeled 
with both fluorochomes and hybridized to Big-Array 23 (Fig. 17}, the range of change in 
expression values between the two samples was only 0.3 or about 0.15 in either direction 
around the no change in expression axis. Therefore, it is possible that other genes are 
changing significantly in expression levels between the two angiogenesis environments 
studied, but the threshold value of 1.5 is eliminating them. 
I 
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I 
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Figure 24. 
Gene expression differences between the two angiogenesis phenotypes 
observed in this study. 
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Figure 25. 
Scatter plot of Figure 24 data showing a low correlation between the two types of 
angiogenesis environments studied. 
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Certain patterns of genes were also revealed between the two angiogenic 
environments. For example, smooth muscle cell specific marker gene transcripts for 
SM22a and a-actin were both upregulated in the polymer implant healing tissue at five 
weeks while SMC-myosin exhibited slightly under no change. In the tumor tissue, 
SM22a and SMC-myosin exhibited no change while a-actin was downregulated. These 
preliminary results suggest that the polymer implant tissue formed a more mature 
vasculature. Further analysis revealed that the transcripts for cadherin-VE and cadherin-3 
exhibited no change in the polymer implant tissue while cadherin-N was upregulated 
slightly. In the tumor tissue, however, Cadherin-VE and Cadherin-3 were upregulated 
over I fold, while Cadherin-N was upregulated slightly. This large difference in the 
presence of Cadherins, which are cell-cell adhesion molecules, may further suggest that 
the stability (and in fact the maturity) of the vasculature in the polymer implant tissue at 
five weeks is greater than that of the tumor vasculature. Genes that were upregulated 
significantly in both cases were Integrin BS, TIE-I, TGFB-1, TIMP-2, FLK-1, and 
Neuropilin. Although it is difficult to pinpoint whether these are a coordinated group of 
genes required for all types of angiogenesis to occur from this study, these results suggest 
that these six genes may be important in the angiogenic process. 
Clearly, expression of mRNA alone is not sufficient to establish functional 
associations among proteins, since the amount of mRN A transcribed does not always 
correlate to the amount of protein translated (44). Additionally, this survey only 
constituted 58 genes thought relevant to angiogenesis by an intense literature search and 
probably represents less than 1% of the entire mouse genome. Finally, no effort was 
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made to select specific cDNA's made by healing tissue or tumor tissue, so certain 
specific genes relevant to these situations may have been missed. In lieu of this, 
however, the type of expression data presented here is very useful as a preliminary study 
and does provide the basis for further hypotheses. Furthermore, the interplay of 
particular groups of genes in the angiogenic process can be elicited from this small group 
of genes, as evidenced by the differential expression of transcription factors in both 
situations, such as ETS-1, which is required for the formation of new blood vessels (30). 
Coordinated changes in expression of many genes may be due to the action of a single or 
small amount of transcription factors (such as ETS-1) and this type of interplay could be 
elicited from the microarray used in this study with the help of a SOM or some type of 
cluster analysis software. In order to obtain information on all of the genes involved for 
the two types of angiogenesis situations looked at for this study, and thus a more 
complete study of angiogenesis, the entire mouse genome would need to be printed on 
DNA microarrays. This would involve making a normalized cDNA library and 
establishing a way to retrieve, store, and analyze the data. These types of experiment 
would yield a wealth of information about the physiology and pathology of angiogenesis. 
Additionally, the establishment of other models for studying angiogenesis, such as 
ischemic tissue and natural wound healing responses, combined with DNA microarrays, 
would further contribute to a greater understanding of the complex process of 
angiogenesis. 
Gene Name 
Angiopoetin-2 
Endoglin 
lntegrin A6 
Integrin AV 
Integrin Bl 
Integrin BS 
Laminin-5 
Tie-I 
Tie-2 
Cadherin-N 
Cadherin-VE 
Cadherin-3 
CD34 
Vitronectin 
Fibronectin 
Connexin-43 
ETS-1 
FGF-1 
FGF-2 
APPENDIX A 
Primer Sequences 
Forward Primer 
agcagctgagagctcaggac 
aggtgacgtttaccaccagc 
accgaggtcacctttgacac 
acactttgggctgtggaatc 
tgggacaggagaaaatggac 
agtactttggcaatccacgg 
accacctctgaacaccaagg 
aacggttctcaccaggtcac 
gagacagaccctgcttttgc 
agggtggacgtcattgtagc 
cttcaagctgccagaaaacc 
gatgatggggaccatttcac 
ctgacttgagaaagctgggg 
tgtttgagcactttgccttg 
accagattggtgactcctgg 
tggacaaggtccaagcctac 
agtggacagaaacccacgtc 
ctgaagagtgggcgtaggag 
agcggctctactgcaagaac 
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Reverse Primer 
tttgtgctgctgtctggttc 
gtggttgccattcaagtgtg 
ggcacctgatgttcacacac 
cgccacttaagaagcacctc 
gcattcacaaacacgacacc 
gcttcctcacttcctcgttg 
attggctaggaccacgtgac 
tgacagctctgtccaaaacg 
cttctccctccagcactgtc 
atttgcagtgttcctgtccc 
aaactgcccatacttgaccg 
tgatgttcagcacttgaggc 
atgccactttcctgcatacc 
tgggtagggaggattcacag 
tgtggttcatctccctcctc 
gacgtgagaggaagcagtcc 
tgcaaggtgtctgtctggag 
tggatactcaggaaaacccg 
tatggccttctgtccaggtc 
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Gene Name Forward Primer Reverse Primer 
FGFR-2 tgtctgcaaggtttacagcg gaagtctggcttcttggtcg 
FLK-I tctttcggtgtgttgctctg tctgtctggctgtcatctgg 
FLT-I acgatggcaacagggtagac atctatggtcttcccccacc 
PECAM ctgagcctagtgtggaagcc gccattaactagcgcctctg 
SM22 ggctcaattcttgaaggcag ggctaaggataggtgggagc 
sMAD-7 tcctgctgtgcaaagtgttc ttgttgtccgaattgagctg 
TGFJ3-I tgagtggctgtcttttgacg tggttgtagagggcaaggac 
TGFJ3-2 acttttgaccgtgaagtggc gacgcagaaaaggctgaaac 
TGFJ3R-2 atgcatccatccacctaagc atgacagctatggcaatccc 
VEGF-A agcacagcagatgtgaatgc aggaatcccagaaacaaccc 
EGR-I tggtggagacgagttatccc aggtctccctgttgttgtgg 
ELAM-I tggtagttgcactttctgcg gagagcacctccaccttctg 
ICAM cctgtttcctgcctctgaag gtctgctgagacccctcttg 
NFkB ccttctaaaggctggtgctg aatagacccaccaagtcccc 
Vezfl tgcatgagtgaggagaccag atgtcataggagtgggcagg 
Ephrin-B2 acaggtgggaggtgactgac tgctttgctttgacatggag 
iNOS gtggtgacaagcacatttgg ggctggacttttcactctgc 
eNOS tctgtcagttcagcacccag ctgtcctcaggaggtcttgc 
SMC-myosin caagaagcaggaactggagg cagctgcatcttgagctctg 
Thrombospondin-I tcaagtttgcaacaagcagg tgtcatagtcttcctgcccc 
Thrombospondin-2 gaaccagctgagcaagaacc atgaagaccagggtgaccag 
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Gene Name Forward Primer Reverse Primer 
TIMP-2 gcatcacccagaagaagagc tgtccctccagacccactac 
Collagen-I actggtacatcagcccgaac atatttttggcttttggggg 
Collagen-IV aggatgcaacggtacaaagg tttttcaccgtctttcccag 
IL-la. tctttgaagttgacggaccc aggccacaggtattttgtcg 
MEF-2 ggaagcggaatgagagacag tcgggaaaactggaacagac 
Collapsin-1 cagccatgtacaacccagtg ggctctctgtgacttcggac 
MMP-9 caatccttgcaatgtggatg attttggaaactcacacgcc 
MMP-MT agtcagggtcacccacaaag catcactgcccatgaatgac 
fos aaaacaaacaaacccgcaag tcatttcctcgttgggtctc 
jun tcccctatcgacatggagtc aaagtccatcgttctggtcg 
GATA-4 tctcactatgggcacagcag cttttccagagctccacctg 
MDK-5 acgctgaaggtgggatacac tcatatcccagtagggtcgc 
Neuropilin ggagctactgggctgtgaag agagccggacatgtgatacc 
NK-1 Receptor cgtggttgtgtgtaccttcg tgaccttgtacacgctgctc 
Stromelysin caggtgtggtgttcctgatg gccttggctgagtggtagag 
SMC a.-Actin agacagctatgtgggggatg gaaggaatagccacgctcag 
vWF aacggaagtccatggttctg agtgtttgtcctattgccgc 
SERCA gccaccctggctgaacccttggctgc ttcccctcctggactcagcttctggg 
Cy-3 Oligo cgggatggatcttgaagggg 
Cy-5 Oligo cttcgattatcttcaagagg 
I) cDNA synthesis for PCR 
I µl embryo RNA (~I µg) 
APPENDIXB 
Protocols 
I µl oligo-dT (~0.5 µg) (Gibco BRL) 
8 µl nuclease free H20 
Heat for IO minutes at 65° C. Then quick chill on ice and add the following: 
4 µl 5X 1st strand reaction buffer (Gibco BRL) 
2 µl 100 mM DTT 
0.8 µl 25 mM dNTP mix 
0.5 µl RNase Inhibitor (40 U/µl, Promega) 
0.5 µl Superscript II RT (200 U/µl, Gibco BRL) 
Incubate at 42° C for I hour and then at 95° C for 5 minutes. 
2) I 00 µl PCR reactions 
IO µl I OX PCR buffer 
IO µl 2.5 mM dNTP's 
IO µl IO µM forward primer 
IO µl IO µM reverse primer 
54 µl dH20 
I µl Taq Polyemrase (.4U/rxn, 5U/µl) 
5 µl cDNA 
100 µl Total 
3) Labeling of PCR products with a Fluorochrome 
2 µl 
2.5 µl 
2 µl 
2 µl 
10.3 µl 
I OX PCR buffer 
2.0 mM low C dNTP's* 
IO µM Forward Primer 
IO µM Reverse Primer 
dH20 
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0.2 µI Taq Polymerase (.4U/rxn, 5U/µI) 
1 µI cDNA 
0.5 µl Cy-3 or Cy-5 (1 mM) 
20.5 µl Total 
*low C dNTP mix: 
20 µl of 100 mM A, T, G nucleotides (Amersham) 
10 µl of 100 mM C nucleotide (Amersham) 
930 µl dH20 
4) Labeling of Total RNA with Fluorochrome 
To a PCR tube, add: 
15 µg Total RNA 
up to 11 µI DEPC-treated H20 
2.5 µl Oligo-dT (500 µg/mL) (Gibco BRL) 
Heat mixture for 10 minutes at 70° C. Transfer to ice for 30 seconds. 
Add the following: 
3.0 µl Cy-3 or Cy-5 (1 mM) 
6.0 µl 5X 1st Stand Buffer (Gibco BRL) 
3.0 µl OTT (100 mM) 
0.6 µl 25 mM low C dNTP's* 
2.0 µl Superscript II RT (200 U/µl, Gibco BRL) 
1 µI RNase Inhibitor ( 40 U/µl, Promega) 
Total: ~30 µl per tube 
Incubate at 42° C for 2 hours. Place on ice. 
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